All In Biotech

Drug Trial Radar · NCT06895343

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-701 in Healthy Adult Western and Asian Subjects

Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Actual

Start

Apr 3, 2025

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single ascending doses of ABBV-701 in healthy adult western and Asian participants.

Conditions

  • Healthy Volunteer

Interventions

  • ABBV-701Drug

    Subcutaneous

  • PlaceboDrug

    Subcutaneous

  • ABBV-701Drug

    IV Infusion

  • PlaceboDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 47 weeks
  2. Maximum Plasma Concentration (Cmax) of ABBV-701Time frame: Up to approximately 47 weeks
  3. Time to Cmax (Tmax) of ABBV-701Time frame: Up to approximately 47 weeks
  4. Apparent terminal phase elimination rate constant (β) of ABBV-701Time frame: Up to approximately 47 weeks
  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-701Time frame: Up to approximately 47 weeks
  6. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-701Time frame: Up to approximately 47 weeks
  7. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-701Time frame: Up to approximately 47 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel ACT- Anaheim Clinical Trials /ID# 278431

    Anaheim, California

  • Acpru /Id# 273354

    Grayslake, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.